| Drug Name: | Esmolol (100286-90-6) |
|---|---|
| PubChem ID: | 59768 |
| SMILES: | CC(C)NCC(COC1=CC=C(C=C1)CCC(=O)OC)O |
| InchiKey: | AQNDDEOPVVGCPG-UHFFFAOYSA-N |
| Therapeutic Category: |
| Molecular Weight (dalton) | : | 295.379 |
| LogP | : | 1.5299 |
| Ring Count | : | 1 |
| Hydrogen Bond Acceptor Count | : | 5 |
| Hydrogen Bond Donor Count | : | 2 |
| Total Polar Surface Area | : | 67.79 |
This panel provides information on interacting drugs and their ADRs along with references
| Interacting drug | Toxicity | Interaction Type | Mechanism | Reference |
|---|
This panel provides drug-protein interaction and their ADRs along with references
| Toxicity | Interacting Protein | Mechanism | Reference |
|---|---|---|---|
| Apoptosis | DNA topoisomerase 1 (P11387) | Rat thymocytes were treated in culture with prednisolone or the DNA topoisomerase I or II inhibitors@The appearance of apoptotic cells in cultures treated with pharmacological concentrations of these drugs@ observed as early as 3-6 hr after treatment@ coincided with the selective loss of G0 cells in these cultures [ ADR Type 1 ] | Apoptosis of rat thymocytes triggered by prednisolone, camptothecin, or teniposide is selective to G0 cells and is prevented by inhibitors of proteases |
| Diarrhoea | Thiopurine S-methyltransferase (P51580) | Diarrhoea [ ADR Type 2 ] | Pharmacogenetics in cancer chemotherapy: balancing toxicity and response |
| Dna Degradation | DNA topoisomerase 1 (P11387) | Different response of HL-60 cells to camptothecin@ teniposide@ or amsacrine via stabilization of the cleavable DNA-topoisomerase complexes through the pathway of rapidly triggered DNA degradation in S phase [ ADR Type 3 ] | Camptothecin, teniposide, or 4'-(9-acridinylamino)-3-methanesulfon-m-anisidide, but not mitoxantrone or doxorubicin, induces degradation of nuclear DNA in the S phase of HL-60 cells |
| Myelosuppression | Thiopurine S-methyltransferase (P51580) | Myelosuppression [ ADR Type 1 ] | Pharmacogenetics in cancer chemotherapy: balancing toxicity and response |
| Selective Prodrug Activation | Carboxylesterase 2 (O00748) | hCE-2 was 26-fold more active than human carboxylesterase 1 and was 65% as active as rabbit liver carboxylesterase, the most active CPT-11 hydrolyzing enzyme known These results confirm the importance of hCE-2 for CPT-11 activation and underscore the importance of enzyme kinetics for selective prodrug activation [ ADR Type 1 ] | Identification and activities of human carboxylesterases for the activation of CPT-11, a clinically approved anticancer drug |
This panel provides drug-food interactions and their ADRs along with references
| Food | Toxicity | Reference |
|---|
This panel provides information on metabolites and their ADRs along with references
| Metabolite | Toxicity | Place of Metabolism | Mechanism | Reference |
|---|
This panel provides information on drug category